Abstract:Background: High mobility group protein B3 (HMGB3) is abundantly expressed in a number of malignancies, contributing to tumor cell growth and predicting poor outcomes. More research on the connection between HMGB3 and breast cancer is needed. The prognostic significance of HMGB3 in breast cancer was examined and validated in this study. Methods: Using The Cancer Genome Atlas (TCGA) database RNA sequencing and clinical data, we investigated the associations between HMGB3 expression and tumor mutations, prognosis, and immune infiltration in breast cancer. The Gene Expression Profiling Interactive Analysis (GEPIA), Tumor Immune Estimation Resource (TIMER), breast cancer gene-expression miner (bc-GenExMiner), UALCAN, OncoLnc, cBio Cancer Genomics Portal (cBioPortal), and LinkedOmics databases were applied to examine the levels of expression, mutation, coexpression, and immune correlation of HMGB3 in breast cancer. cBioPortal and the Database for Annotation, Visualization, and Integrated Discovery (DAVID) were used for coexpression and enrichment analyses, respectively. Experimental tests and a separate cohort of breast cancer patients in our center were used for validation. To determine independent risk factors affecting breast carcinoma prognosis, multivariate Cox regression analysis was performed. The Kaplan-Meier method was applied to analyze the connection between HMGB3 expression and overall survival time in breast cancer. Results: Pan-cancer investigation using the GEPIA and UALCAN databases revealed a high level of HMGB3 expression in different malignancies, including breast cancer. HMGB3 might be a potential diagnostic biomarker, according to the receiver operating characteristic (ROC) curve (AUC=0.932). And immunohistochemistry confirmed higher HMGB3 protein expression in breast cancer tissues in clinical samples. Experimental tests also showed that breast cancer cells have higher expression of HMGB3, and knockdown of HMGB3 can promote the proliferation of breast cancer cells and increase sensitivity to chemotherapy. Human epidermal growth factor receptor 2 (HER2), Nottingham Prognostic Index (NPI), basal-like status, nodal status (N+), triple-negative status, and Scarff-Bloom-Richardson (SBR) grade all showed positive correlations with HMGB3 expression. Conversely, HMGB3 expression was negatively associated with the expression of estrogen receptor (ER) and progesterone receptor (PR) in breast cancer. Breast cancer patients with high HMGB3 expression had poor overall survival, which was validated by an analysis of a separate cohort of breast cancer patients in our center. Cox regression analysis identified high HMGB3 expression as an independently associated risk factor for breast carcinoma. The amount of immunological infiltration was substantially linked with the high expression of HMGB3. The chromosome centromeric region, ATPase activity, and the cell cycle are critical areas where HMGB3 is involved, according to enrichment analysis. Therefore, we suspected that HMGB3 might be a potential biomarker for detecting and treating breast carcinoma. Conclusion: Breast cancer tissues had higher HMGB3 expression than normal breast tissues. HMGB3 overexpression may serve as an indicator for poor breast cancer outcomes.

Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients

Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.

Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.

Intratumoral Expression Of Ccr3 In Breast Cancer Is Associated With Improved Relapse-Free Survival In Luminal-Like Disease

Apobec3g Expression is Correlated with Poor Prognosis in Colon Carcinoma Patients with Hepatic Metastasis

Profiles of Acetylation Regulation Genes Contribute to Malignant Progression and Have a Clinical Prognostic Impact on Liver Cancer

Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes

Identification of Histone Deacetylase 3 As a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-associated Hepatocellular Carcinoma.

DIRAS3, GPR171 and RAC2 were identified as the key molecular patterns associated with brain metastasis of breast cancer

Overexpression of HMGB3 and its prognostic value in breast cancer

Expression and Regulation Network of HDAC3 in Acute Myeloid Leukemia and the Implication for Targeted Therapy Based on Multidataset Data Mining

Transcriptome-based network analysis related to histone deacetylase genes and identified EMP1 as a potential biomarker for prognosis in bladder cancer

Abstract 4139: Prolyl 4-hydroxylase subunit alpha 1 acts as a novel target for lung adenocarcinoma brain metastasis

Identification of HDAC10 as a candidate oncogene in clear cell renal carcinoma that facilitates tumor proliferation and metastasis

Abstract P3-05-46: Scrna-Seq Profiling Reveals Different Tumor Immune-Microenvironment in Triple Negative Breast Cancer and Decodes Pivotal Role of THBS1- SDC1 Axis in Tumor Metastasis

Histone Deacetylase HDAC1 Expression Correlates with the Progression and Prognosis of Lung Cancer: A Meta-Analysis.

A computational analysis of the oncogenic and anti-tumor immunity role of P4HA3 in human cancers

HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells

Upregulation of ZMAT3 is Associated with the Poor Prognosis of Breast Cancer

The Expression of Histone Deacetylase HDAC1 Correlates with the Progression and Prognosis of Gastrointestinal Malignancy

Bioinformatic analysis reveals an association between Metadherin with breast cancer prognosis and tumor immune infiltration